A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2102 in Healthy Adult
Phase 1
Recruiting
- Conditions
- Respiratory Syncytial Virus Infections
- Registration Number
- NCT06313697
- Lead Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 132
Inclusion Criteria
Inclusion Criteria:<br><br> 1. Healthy adult subjects<br><br> 2. Signed informed consent<br><br>Exclusion Criteria:<br><br> 1. Signs and symptoms of upper respiratory tract infection prior to randomization<br><br> 2. Prior use of RSV vaccine or RSV antibody-based medications<br><br> 3. history of malignant tumor
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Adverse events
- Secondary Outcome Measures
Name Time Method Maximum Observed Serum Concentration;Terminal Elimination Half Life;anti-respiratory syncytial virus neutralizing antibodies titer levels